Citius Oncology partners with EVERSANA for LYMPHIR drug launch

Citius Oncology Inc. (NASDAQ: CTOR) announced it has signed an exclusive commercialization agreement with EVERSANA to support the planned fourth quarter 2025 U.S. launch of LYMPHIR, its FDA-approved therapy for cutaneous T-cell lymphoma.

Under the Master Service Agreement, EVERSANA will provide integrated pre- and post-launch services including medical information, pharmacovigilance, revenue cycle management, program management, data and analytics, and channel management. Additional commercialization services are expected to be added as launch preparations advance.

LYMPHIR (denileukin diftitox-cxdl) received FDA approval in August 2024 for treating relapsed or refractory cutaneous T-cell lymphoma in patients who have had at least one prior systemic therapy. The drug targets the IL-2 receptor on malignant T-cells and regulatory T-cells.

"Finalizing our exclusive agreement with EVERSANA is a transformative milestone as we prepare and plan to bring LYMPHIR to market in Q4 2025," said Leonard Mazur, chairman and CEO of Citius Oncology.

Cutaneous T-cell lymphoma is a type of non-Hodgkin lymphoma where T-cells become cancerous and develop into skin lesions. The disease affects men twice as often as women and is typically diagnosed in patients between ages 50 and 60. Currently, no curative therapy exists for advanced stages of the disease except allogeneic stem cell transplantation, which only a small fraction of patients qualify for.

Citius Oncology is the oncology-focused subsidiary of Citius Pharmaceuticals Inc. (NASDAQ: CTXR). The information in this article is based on a press release statement from the company.

You May Also Be Interested In

• Paramount Skydance extends bond offer deadlines to August 7
• Capstone Energy (CEPL) files mixed shelf
• Replimune (REPL) files for 25.1M share offering by selling stockholders